Nasdaq nmra.

Neumora Therapeutics, Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics, Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.20 Nov 2023 ... NMRA:NSQNASDAQ. Neumora Therapeutics Inc. Actions. Add to watchlist; Add ... Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, ...Neumora Therapeutics, Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics, Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.Research Neumora Therapeutics' (Nasdaq:NMRA) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, ... It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; ...Find the latest Earnings Report Date for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.

When is Neumora Therapeutics (NASDAQ:NMRA) reporting earnings? A. Neumora Therapeutics ( NMRA) is scheduled to report earnings on February 15, 2024. The last reported earnings were for reported on ...

Stock Quote. NASDAQ GS: NMRA. $12.33. Dec 1, 2023 4:00 PM EST. Change. +0.08 (+0.65%). Volume. 232,481. Today's Open. $12.24. Previous Close. $12.25. Today's ...About This Event Neumora Therapeutics, Inc. (Nasdaq: NMRA), visits the Nasdaq MarketSite in Times Square. Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to ...

Get the latest Neumora Therapeutics Inc (NMRA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Andrey Tolkachev/iStock via Getty Images. Neumora Therapeutics (NASDAQ:NMRA) stock dipped 4% in late afternoon trading Friday following a $250M IPO.Shares of the psychiatric drug developer opened ...Find the latest news headlines from Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com. Christoph Burgstedt/iStock via Getty Images. Company logo. I started a long position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) last week with a 4.2% portfolio allocation.This recent central ...Neumora Therapeutics (NASDAQ:NMRA) stock dipped 4% in late afternoon trading Friday following a $250M IPO. Shares of the psychiatric drug developer opened at $16.50 after being priced at $17 per ...

Neumora Therapeutics (NASDAQ:NMRA) stock dipped 4% in late afternoon trading Friday following a $250M IPO. Shares of the psychiatric drug developer opened at $16.50 after being priced at $17 per ...

Avenue Therapeutics, Inc. (NASDAQ: ATXI) shares rose 33.4% to $0.2326 in pre-market trading after falling 8% on Wednesday. Robert Davidow reported a14.5 % passive stake in Avenue Therapeutics in a ...

Atomera Inc (NASDAQ:ATOM)’s traded shares stood at 0.16 million during the last session, with the company’s beta value hitting 1.45. At the close of trading, the stock’s price was $6.97, to imply an increase of 0.29% or $0.02 in intraday trading. The ATOM share’s 52-week high remains $10.72 ...Find the latest news headlines from Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com. Quais ferramentas de análise técnica podem ser usadas para analisar Neumora Therapeutics, Inc.? Confira vários osciladores, médias móveis e outros indicadores …Navacaprant is an investigational once-daily oral medication that is designed to modulate the dopamine and reward processing pathways. Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, NMRA-CK1d, NMRA-NLRP3, and NMRA-GCase. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR).In addition, NMRA-266 (M4R PAM), another drug in development for the treatment of schizophrenia, is viewed as a de-risked asset due to the large market and low entry barriers for this disease.Neumora Therapeutics, Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics, Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.

$8.11 +0.06 +0.75% Find the latest Financials data for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com. Neumora Therapeutics, Inc. (NASDAQ:NMRA) as filed to raise $100 million in an IPO of its common stock, according to an SEC S-1 registration statement.NMRA-266 is an investigational positive allosteric modulator of the M4 muscarinic receptor subtype, a clinically validated target for the treatment of schizophrenia. Neumora exclusively licensed ...Neumora Therapeutics (NASDAQ: NMRA), a biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, went public on September 15th with ...Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder WATERTOWN, Mass.--(BUSINESS WIRE)--Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the planned initiation of the …

VinFast Auto Ltd. (NASDAQ:VFS) gained 13.6% to $12.73 following a report suggesting the company is planning to set up a manufacturing plant in India. Neumora Therapeutics, Inc. (NASDAQ:NMRA ...NASDAQ: NMRA. $11.69-0.16 (-1.35%) Updated Nov 21, 2023. Open eToro Account. FAQ. How much does it cost to buy one Neumora Therapeutics share? As of . Nov 21, 2023, it costs $11.69 to buy one share of Neumora Therapeutics stock.Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs.

6 hari yang lalu ... (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will ...--Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Robert Lenz, M.D., Ph.D., as executive vice ...Neumora Therapeutics has raised a total of. $612M. in funding over 4 rounds. Their latest funding was raised on Oct 11, 2022 from a Series B round. Neumora Therapeutics is registered under the ticker NASDAQ:NMRA . Their stock opened with $16.50 in its Sep 15, 2023 IPO. Neumora Therapeutics is funded by 18 investors.Nov 1, 2023 · WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ... Nov 18, 2023 · Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) major shareholder Arch Venture Partners Xii, Llc bought 3,357 shares of the company’s stock in a transaction on Tuesday, November 14th. Member FINRA / SIPC / NYSE / NASDAQ / CBOE EDGX. Webull offers NMRA Ent Holdg (NMRA) historical stock prices, in-depth market analysis, NASDAQ: NMRA real-time stock quote data, in-depth charts, free NMRA options chain data, and a fully built financial calendar to help you invest smart. Buy NMRA stock at Webull. Neumora Therapeutics press release (NASDAQ:NMRA): Q3 GAAP EPS of -$1.14 misses by $0.74. $519.5 million in cash, cash equivalents and marketable securities expected to support operations into 2026.NMRA Neumora Therapeutics, Inc. Stock Price & Overview. Follow 212 followers. $12.250.00 (0.00%)11:37 AM 12/01/23. NASDAQ | $USD | Realtime. Summary · Ratings ...Sep 12, 2023 · A Quick Take On Neumora Therapeutics. Neumora Therapeutics, Inc. ( NASDAQ: NMRA) has filed proposed terms to raise $250 million from the sale of its common stock in an IPO, according to an amended ... Nov 22, 2023 · Navacaprant is an investigational once-daily oral medication that is designed to modulate the dopamine and reward processing pathways. Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, NMRA-CK1d, NMRA-NLRP3, and NMRA-GCase. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR).

Which Neumora Therapeutics insiders have been buying company stock? The following insiders have purchased NMRA shares in the last 24 months: Amgen Inc ($29,999,985.00), Arch Venture Partners Xii, Llc ($2,626,582.57), Henry O Gosebruch ($189,300.00), and Kristina Burow ($28,803,319.17).

Fiscal Q3 2023 ended 9/30/23. Get the latest Neumora Therapeutics Inc (NMRA) real-time quote, historical performance, charts, and other financial information to help you make more informed...

Sep 21, 2023 · Investors can buy NMRA even cheaper than Gosebruch did, with shares changing hands as low as $10.01 at last check today -- that's 20.7% under Gosebruch's purchase price. VIDEO: Thursday 9/21 ... Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) major shareholder Arch Venture Partners Xii, Llc bought 3,357 shares of the company’s stock in a transaction on Tuesday, November 14th.Nov 1, 2023 · WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ... 10 Okt 2023 ... Market Conditions: The broader stock market experienced a mixed situation on October 2, 2023. This can be attributed to concerns such as ...View live price data for NMRA (Neumora Therapeutics, Inc.) on TrendSpider to track real-time price action, options flow, and news on this asset and hundreds more. Dark Light. Search Ctrl + K. Login Try full version. Smart Watchlists. NMRA. NMRA. Neumora Therapeutics, Inc. 10.02 USD +0.38 (+3.94%) Last updated Oct 13, 21:00 UTC. …Minim, Inc. (NASDAQ: MINM) gained 29.3% to $1.19 in pre-market trading after gaining over 13% on Wednesday. ... (NASDAQ: NMRA) gained 15.4% to $14.00 in pre-market trading. Neumora Therapeutics ...2 hari yang lalu ... Read William Blair Brokers Cut Earnings Estimates for Neumora Therapeutics, Inc. (NASDAQ:NMRA) at Techdows.NMRA-266 is an investigational positive allosteric modulator of the M4 muscarinic receptor subtype, a clinically validated target for the treatment of schizophrenia. Neumora exclusively licensed ...Neumora Therapeutics (NASDAQ:NMRA) stock dipped 4% in late afternoon trading Friday following a $250M IPO. Shares of the psychiatric drug developer opened at $16.50 after being priced at $17 per ...

On October 10, 2023, Geoff Meacham, an analyst at Bank of America Securities, commenced coverage on Neumora Therapeutics (NASDAQ:NMRA) by Analyst Coverage and Price Targets for Neumora Therapeutics - Best StocksNeumora Therapeutics (NASDAQ:NMRA) stock dipped 4% in late afternoon trading Friday following a $250M IPO. Shares of the psychiatric drug developer opened at $16.50 after being priced at $17 per ...27 Sep 2023 ... See the latest Neumora Therapeutics Inc stock price (NASDAQ:NMRA), related news, valuation, dividends and more to help you make your ...NVDA. NVIDIA Corporation Common Stock. $449.995 +1.295 +0.29%. Neumora Therapeutics, Inc. Common Stock (NMRA) Advanced Charting - Nasdaq offers …Instagram:https://instagram. steel pennyscignaplus savings dental providerspeloton bike refurbishedwhat is vtsax Nov 8, 2023 · Within the last quarter, Neumora Therapeutics (NASDAQ:NMRA) has observed the following analyst ratings: According to 6 analyst offering 12-month price targets in the last 3 months, Neumora ... Nov 1, 2023 · Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the global brain disease ... eye insurance californiaupgrade downgrade stocks On Wednesday, Neumora Therapeutics Inc. [NASDAQ: NMRA] rose 1.88% to $11.91. The stock’s lowest price that day was $11.76, but it reached a high of $12.14 in the same session. During the last five days, there has been a drop of approximately -0.83%. Over the course of the year, Neumora Therapeutics Inc. shares have dropped approximately -26.71%. roots reit review WATERTOWN, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the ...In addition, NMRA-266 (M4R PAM), another drug in development for the treatment of schizophrenia, is viewed as a de-risked asset due to the large market and low entry barriers for this disease.Neumora Therapeutics (NASDAQ:NMRA) stock dipped 4% in late afternoon trading Friday following a $250M IPO. Shares of the psychiatric drug developer opened at $16.50 after being priced at $17 per ...